Catheterization News and Research

RSS

Summa Health System to implement ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Summa Health System has selected ProVation® MD software for Cardiology procedure documentation and coding.

6 Oct 2009

Stem cell therapy aims to prevent permanent damage from heart attacks

All patients arriving at UCSF's Emergency Department with heart attack will continue to be treated with standard measures. Patients who meet the medical criteria for the trial will be able to elect to receive the stem cell therapy within seven days after their heart attack.

1 Oct 2009

Cost-effective screening test for coronary artery disease

A simple, non-invasive test appears to be an effective screening tool for identifying patients with silent heart disease who are at risk for a heart attack or sudden death.

1 Oct 2009

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%,>

25 Sep 2009

Z-Medica launches the QuikClot Interventional hemostatic bandage for use during catheterization procedures

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced the availability of the QuikClot® Interventional™ hemostatic bandage, on display at booth #1338 at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

From Medica Corporation 24 Sep 2009

St. Jude Medical's cardiovascular healthcare portfolio to be presented at TCT meeting

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company’s portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company’s continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.

23 Sep 2009

New heart surgery method raises questions for reformers

A new method for performing cardiac catheterizations may be more comfortable, shows a lower chance of complications such as severe bleeding, and allows patients to be discharged more quickly, potentially saving money, the Washington Post reports.

23 Sep 2009

FemSoft from Rochester Medical included in the UK Drug Tariff

Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company's FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.

22 Sep 2009

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the PressureWire™ Aeris technology, an interventional tool which measures Fractional Flow Reserve (FFR) to evaluate the severity of blood flow blockages in the arteries. This first-to-market technology helps interventional cardiologists better determine the ideal treatment option for their patients during coronary interventions, such as stent procedures.

22 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

AFib ablated using visually-guided laser balloon catheter

Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation using a visually-guided laser balloon catheter.

21 Sep 2009

Black patients less likely to survive cardiac arrests in hospitals

Black patients have lower rates of successful resuscitation and are less likely to survive an in-hospital cardiac arrest compared to white patients, according to a study in the Sept. 16 issue of the Journal of the American Medical Association.

16 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

HFSA annual meeting features discussion on David Duncan's quest for personalized medicine

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion by David Ewing Duncan titled "One Man's Quest for Personalized Medicine." Over the course of one year, Duncan submitted himself to hundreds of tests that could predict and even prevent future illness.

14 Sep 2009

First patient enrolled in Phase 2b RADAR clinical trial

Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.

11 Sep 2009

Successful results on Surinate Bladder Management System

Urovalve announced today the successful results of a feasibility study of the Valve component of its Surinate® Bladder Management System—designed to improve the quality of life of men who suffer from acute or chronic urinary retention, which is an inability to empty the bladder caused by obstruction of the urethra.

9 Sep 2009

Strata brands of Foley catheters launched by Rochester Medical Corporation

Rochester Medical Corporation (Nasdaq: ROCM) today announced the introduction of its Strata brands of Foley catheters. This new Foley product line features proprietary comfort layered technology. The company's StrataSI(TM) catheter is all-silicone, while the StrataNF(TM) version includes a nitrofurazone anti-infective matrix within the silicone.

4 Sep 2009

Primary angioplasty procedures vary in European countries

Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.

2 Sep 2009